Healthcare / Medical Care FacilitiesJakarta
$1050.00
+105.00 (+11.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-94.7B · quality 60.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.17T
P/E
53.4x
↑EV/EBITDA
14.4x
↑ROE
3.0%
↑Gross Margin
29.8%
↓Debt/Equity
0.52
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+18.2%
FCF CAGR
—
FCF margin
-7.0%
FCF / Net income
-2.17x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.36T · net income $43.62B · FCF $-94.69B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1357.85B | $1357.85B | $1067.78B | $921.91B | $822.29B |
| Net Income | $43.62B | $43.62B | $5.18B | $-12.83B | $65.96B |
| EBITDA | $202.93B | $202.93B | $117.99B | $80.11B | $160.46B |
| EPS | — | — | 2.50 | -6.20 | 33.00 |
| Gross Margin | 29.8% | 29.8% | 25.3% | 24.4% | 26.5% |
| Operating Margin | 8.4% | 8.4% | 2.1% | 1.3% | 8.3% |
| Net Margin | 3.2% | 3.2% | 0.5% | -1.4% | 8.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.52 | 0.52 | 0.48 | 0.44 | 0.32 |
| Current Ratio | 0.42 | 0.42 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-94.69B | $-94.69B | $-70.27B | $-98.96B | $-148.03B |
| Returns | |||||
| ROE | 3.0% | 3.0% | 0.4% | -1.1% | 5.8% |
| Valuation | |||||
| P/E | 53.41 | 53.41 | 390.00 | — | 42.42 |
| EV/EBITDA | 14.38 | 14.38 | 22.58 | 40.72 | 19.43 |
| P/B | 1.47 | 1.47 | 1.46 | 2.47 | 2.46 |
| Growth & Yield | |||||
| Revenue Growth | 27.2% | 27.2% | 15.8% | 12.1% | — |
| EPS Growth | — | — | 140.3% | -118.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+10.5%
Start / end P/E
n/dx → n/dx
EPS bridge
2.50 → n/d
Residual
+10.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.